Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Yaoxue Xuebao

Volumn 39, Issue 8, 2004, Pages 666-672

  Zhou, Ting ^a   Xie, Lan ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

AIDS; HIV; NNRTIs; Reverse transcriptase

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; 12 OXOCALANOLIDE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 6 CHLORO 2 [(1 FURO[2,3 C]PYRIDIN 5 YLETHYL)THIO] 4 PYRIMIDINAMINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYL 3,4 DIHYDRO 4 [(2 PYRIDYL)ETHYNYL] 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALANOLIDE A; CAPRAVIRINE; DELAVIRDINE; DIAZEPINE DERIVATIVE; EFAVIRENZ; ETRAVIRINE; LOVIRIDE; MEN 10979; MSC 204; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; PYRROLOBENZODIAZEPINONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TMC 120; UK 129485; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ACTIVITY; DRUG DESIGN; DRUG INDICATION; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROCESS DESIGN; PROCESS DEVELOPMENT; REVIEW;

ANTI-HIV AGENTS; COUMARINS; DELAVIRDINE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NEVIRAPINE; OXAZINES; PYRANOCOUMARINS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 10644257857     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Zhang WS, Li AL. Medicinal chemistry [M]. Beijing: Higher Education Publishing House, 1999. 506-522.
2. Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase [J]. Antimicrob Agents Chemother, 1995,39(12):2602-2605.
3. Bellarosa D, Antonelli G, Bambacioni F, et al. New arylpyrido-diazepine and thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase [J]. Antiviral Res, 1996,30: 109-124.
4. Corbett JW, Ko SS, Rodgers JD, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1 [J]. Antimicrob Agents Chemotner, 1999,43(12):2893-2897.
5. Wishka DKG, Graber DR, Kopta LA, et al. (-)-6-Chloro-2-[(1-furo[2,3-c] pyridin-5-yl-ethyl) thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor [J]. Antimicrob Agents Chemother, 2001,45:1379-1386.
6. Ludovici DW, Kavash RW, Kukla MJ, et al. Evolution of anti-HIV drug candidates. Part 3: diaryipyrimidine (DAPY) analugues [J]. Bioorg Med Chem Lett, 2001, 11:2235-2239.
7. Rao A, Carbone A, Chimirri A, et al. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives [J]. Il Farmaco, 2002,57:747-751.
8. Rao A, Carbone A, Chimirri A, et al. Synthesis and anti-HIV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones [J]. Il Farmaco , 2003,58:115-120.
9. Vig R, Mao C, Venkatachalm TK, et al. Rational design and synthesis of phenethyl-5 -bromopyridyl thiourea derivatives as potent non-nucleoside inhibitorsof HIV reverse transcriptase [J]. Bioorg Med Chem, 1998,6: 1789-1797.
10. Balzarini J, Brouwer WG, Felauer EE, et al. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains [J]. Antiviral Res, 1995,27:219-236.
11. Borkow G, Barnard J, Nguyen TM, et al. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J]. J Virol, 1997,71(4):3023-3030.
12. Fujiwara T, Sato A, El-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 [J]. Antimicrob Agents Chemother, 1998,42:1340-1345.
13. Buckheit RW, JR, Watson K, et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 [J]. Antimicrob Agents Chemother, 2001,45:393-400.
14. Xu ZQ, Buckheit RW, JR, et al. In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI [J]. Bioorg Med Chem Lett, 1998,8:2179-2184.
15. Creagh T, Ruckle JL, Tolbert DT, et al. Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects [J]. Antimicrob Agents Chemother, 2001,45:1379-1386.
16. Borkow G, Arion D, Wainberg MA, et al. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1 [J]. Antimicrob Agents Chemother, 1999,43:259-263.
17. Ren J, Nichols C, Bird LE, et al. Binding of the second generation non-nucleoside inhibitors S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding [J]. J Biol Chem, 2000,275:14316-14320.
18. Rao A, Chimirri A, De Clercq E, et al. Synthesis and anti-HIV activity of 1- (2, 6-difluoropheny)-1H, 3H-thiazolo [3,4-a] benzimidazole structurally-related 1,2-substituted benzimidazoles [J]. Il Farmaco, 2002,57: 819-823.
19. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J]. Il Farmaco 1999,54:26-45.
20. Yu H, Kalyan D, Ding JP, et al. Structures of tyr188leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance [J]. J Mol Biol, 1998,284:313-323.
21. Parreira RLT, Abrahao O, et al. Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors [J]. Tetrahedron, 2001,57:3243-3253.
22. Barreca ML, Carotti A, Carrieri A, et al. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs) [J]. Bioorg Med Chem, 1999,7:2283-2292.
23. Kalyan D, Ding JP, Yu H, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the tyr181cys HIV-1 RT drug-resistant mutant [J]. J Mol Biol, 1996,264:1085 -1100.
24. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors [J]. AIDS, 2003,17(6):791-799.
25. Wang DP, Rizzo RC, Julian TR, et al. Antiviral drug desigh: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs [J]. Bioorg Med Chem Lett, 2001,11:2799-2802.
26. Ludovici DW, Kukla MJ, Grous PG, et al. Evolution of anti-HIV drug candidates. part 1: from α-anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) [J]. Bioorg Med Chem Lett, 2001,11:2225-2228.
27. Ludovici DW, Kavash RW, Kukla MJ, et al. Evolution of anti-HIV drug candidates, part 2: diaryltriazine (DATA) analogues [J]. Bioorg Med Chem Lett, 2001, 11:2229-2234.
28. Hogberg M, Sahlberg B, Engelhardt P, et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. synthesis and further structure-activity relationship studies of PETT analogues [J]. J Med Chem, 1999,42(20):4150-4160.
29. Esnouf RM, Stuart DI, De Clercq E, et al. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio) carboxanilide derivatives [J]. Biochem Biophys Commun, 1997,234(2):458-464.
30. Balzarini J, Pelemans H, Riess G, et al. Retention of marked sensitivity to HBY097 in the combined presence of quinoxaline HBY097 and lamivudine [J]. Biochem Pharmacol, 1998,55(5):617-625.